Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer

Journal of Clinical Oncology

Volumn 27, Issue 22, 2009, Pages 3575-3576

  D'Amico, Anthony V ^a   Chen, Ming Hui ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER PATIENT; CANCER RISK; EDITORIAL; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME; VELOCITY; AGED; BLOOD; CANCER STAGING; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; MORTALITY; NOTE; PATHOLOGY; POSTOPERATIVE CARE; PREDICTION AND FORECASTING; PREOPERATIVE CARE; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY; SURVIVAL; TIME; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE CARE; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 68949092438     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.6068     Document Type: Editorial

References (16)

1. D'Amico AV, Renshaw AA, Sussman B, et al: Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294:440-447, 2005
2. D'Amico AV, Chen MH, Catalona WJ, et al: Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 110:56-61, 2007
3. D'Amico AV, Chen MH, Renshaw AA, et al: Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol 176:S11-S15, 2006
4. D'Amico AV, Moul J, Carroll P, et al: Cancer specific mortality following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era. J Clin Oncol 21:2163-2172, 2003
5. O'Brien MF, Cronin AM, Fearn PA, et al: Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 27:3591-3597, 2009
6. Wiegel T, Bottke D, Willich N, et al: Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95). J Clin Oncol 25:249s, 2007 (suppl; abstr 5060)
7. Bolla M, van Poppel H, Collette L, et al: European Organisation for Research and Treatment of Cancer: Postoperative radiotherapy after radical prostatectomy: A randomized controlled trial (EORTC trial 22911). Lancet 366: 572-578, 2005
8. Thompson IM, Tangen CM, Paradelo J, et al: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term follow-up of a randomized clinical trial. J Urol 181:956-962, 2009
9. Roach M III, Bae K, Speight J, et al: Short-term neoadjuvant androgen deprivation therapy and external bean radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 26:585-591, 2008
10. Pilepich MV, Winter K, Lawton CA, et al: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61:1285-1290, 2005
11. Denham J, Steigler A, Lamb DS, et al: Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Tran-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6:841-850, 2005
12. D'Amico AV, Chen M, Renshaw AA, et al: Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 299:289-295, 2008
13. D'Amico AV, Whittington R, Malkowicz SB, et al: The clinical utility of the percent of positive prostate biopsies in defining biochemical outcome following radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18:1164-1172, 2000
14. Grossfeld GD, Latini DM, Lubeck DP, et al: Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 169:157-163, 2003
15. Beard C, Schultz D, Loffredo M, et al: Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 66:403-407, 2006
16. Lee IH, Roberts R, Shah RB, et al: Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int J Radiat Oncol Biol Phys 68:1059-1064, 2007